Clinical Trials
2 trialsNCT03079687 2017-10-25
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AstraZeneca
Approved for marketing
NCT03025867 2017-04-17
Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer
Tesaro, Inc.
Approved for marketing